Using advanced MRI to improve diagnosis of muscle-invasive bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial compares two approaches for diagnosing muscle-invasive bladder cancer (MIBC): the standard transurethral resection of bladder tumor (TURBT) and a new method involving multi-parametric MRI (mpMRI) followed by a same-day cystoscopic bladder biopsy. The study aims to evaluate progression-free survival, time to definitive treatment, and cost-effectiveness between these two diagnostic strategies. It is a multicenter randomized controlled trial involving multiple hospitals in the Netherlands.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients (18+ years of age)
* Clinically suspected MIBC
* No lymph node or distant metastases
* Written informed consent

Exclusion Criteria:

* Unable or unwilling to undergo mpMRI
* Unfit for TURBT
* Unfit for definitive treatment with curative intent
* A history of cancer, including bladder cancer, except: non-melanoma skin cancer, prostate cancer on active surveillance or a solid malignant tumor ≥5 years disease-free since last treatment

Where it's running

• Jeroen Bosch ziekenhuis
  's-Hertogenbosch, Netherlands Recruiting
• Ziekenhuisgroep Twente
  Almelo, Netherlands Recruiting
• Amsterdam UMC, location AMC
  Amsterdam, Netherlands Recruiting
• Amsterdam UMC, location VUmc
  Amsterdam, Netherlands Recruiting
• Antoni van Leeuwenhoek - Netherlands Cancer Institute
  Amsterdam, Netherlands Recruiting
• Olvg
  Amsterdam, Netherlands Recruiting

Study contacts

• Principal investigator: A. G. van der Heijden, Dr. — Radboud University Medical Center
• Study coordinator: A. G. van der Heijden, Dr.
• Email: toine.vanderheijden@radboudumc.nl
• Phone: +31 (0)24 361 37 35

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Personalized 3D Tumoroids from Your Tumor to Test Treatments

  Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07820566

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.